Italfarmaco Group and Luye Pharma announced today that they entered into a commercialization agreement for Rivastigmine MD. Under the agreement, Milan, Italy–based Italfarmco receives exclusive rights to commercialize the Rivastigmine multi-day transdermal patch in four European companies, according to a news release. Get the full story at our sister site, Drug Delivery Business News.